Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid initiation of dolutegravir + lamivudine in newly diagnosed HIV infection
ChiCTR2100047490Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by First Hospital of China Medical University. Primary endpoint: HIV-1 viral load. Started Jun 2021; status: recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2100047490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047490.